Navigation Links
Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
Date:5/17/2013

eadership position in anti-infective mAbs. This promising new class of anti-infectives presents very significant advantages over conventional antibiotics that are prone to drug resistance' said Aridis Founder & Chief Scientific Officer Dr. Vu Truong .

This portfolio of mAb products will be folded into Aridis' Switzerland subsidiary to facilitate completion of the ongoing clinical trial and provide access to an excellent range of resources in Switzerland. Our current financing activities will fund the completion of the on-going phase 2a clinical trial in pneumonia patients infected with antibiotic resistant strains of S. aureus (e.g. MRSA, MSSA), and also to advance two additional IND stage products through phase 1 clinical testing. These clinical trials will be completed within 18-24 months.

About Aridis

Aridis Pharmaceuticals is a privately held biopharmaceutical company headquartered in San Jose, CA, with a subsidiary in Switzerland. The Company is focused on the development of novel anti-infective drugs for the treatment of lung infections and other surface infections. Our products target infectious diseases that have a significant impact on life expectancy and address acute unmet medical needs including: nosocomial infections [Hospital acquired pneumonia, ventilator associated pneumonia], lung infections associated with cystic fibrosis, and severe wound infections. Aridis has a best-in-class anti-infective monoclonal antibody which targets P. aeruginosa (AerucinTM). Complementing the mAbs is a broad spectrum anti-infective, gallium citrate (PanaecinTM), which has shown preliminary efficacy and safety in a human clinical trial. The Company is a recognized global leader in biopharmaceutical stabilization formulation technologies and has successfully attained ov
'/>"/>

SOURCE Aridis Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 Regis Technologies ... development of oncology drug substances. , Regis Technologies is ... their new Potent Compound Suite (PCS) for 2015. , ... square foot, cGMP facility in Morton Grove, Illinois. The ... of potent compounds up to about one kilogram per ...
(Date:2/26/2015)... -- Epic Sciences announced today that President and CEO ... Annual Cowen and Company Health Care Conference on Wednesday, March ... Floor. The conference will be held at the Boston ... is developing diagnostic tests of high clinical utility to ... occur during the course of cancer treatments. From a ...
(Date:2/26/2015)... SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2015 ... for the treatment of cancer, today announced that ... present a corporate overview at the upcoming Cowen and ... Boston . Dr. McCarthy,s presentation will ... 2. About CytomX Therapeutics CytomX Therapeutics ...
(Date:2/26/2015)... , February 26, 2015 ... into PEACH, the first pivotal trial of PT20 ... chronic kidney disease (DD-CKD), has completed as the ... PT20, invented by leading UK-based scientists from ... Phosphate Therapeutics, is a novel phosphate binder that ...
Breaking Biology Technology:Regis Extends cGMP Services to Oncology Market 2Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3
... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: OGXI ) announced ... Fast Track designation from the U.S. Food & ... prostate cancer. OGX-011 is currently completing five Phase ... and is designed to,inhibit the production of a ...
... 21 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased ... on August 25, 2008 at 11:00 am MDT ... the presentation there will be a live,question and ... at the following link:, http://services.choruscall.com/links/resverlogix080825.html , ...
... BPUR ) today announced its financial results for the ... the company reported a net,loss of $4.6 million, or ... $6.4 million, or $0.41 per common share, for the ... July 31, 2008 and 2007 were,37,340,051 and 15,592,025, respectively., ...
Cached Biology Technology:FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4Resverlogix Notice of Conference Call & Webcast 2Biopure Announces 2008 Third Quarter Financial Results 2Biopure Announces 2008 Third Quarter Financial Results 3Biopure Announces 2008 Third Quarter Financial Results 4Biopure Announces 2008 Third Quarter Financial Results 5Biopure Announces 2008 Third Quarter Financial Results 6Biopure Announces 2008 Third Quarter Financial Results 7
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E - ... authentication solutions, today announced it will showcase its EyeLock ID ... by the Department of Energy,s Oak Ridge National Laboratory ... Show . EyeLock,s iris identity authentication technology is being used ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , ... source covering leading sectors including technology and tech stocks, releases ... marketplace featuring master pickpocket and security consultant Apollo Robbins ... stolen and talks about the Wocket™ biometric smart wallet, a ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... causing the largest die-off of great whales ever recorded? ... and health experts from the Wildlife Conservation Society have ... by the International Whaling Commission on the Patagonian coast ... urgent mystery. At issue is the long-term conservation ...
... D.C., March 16, 2010 Primary care physicians agree they ... not have the right weight management resources. Obese or ... need to lose weight may lack information about effective weight ... from new research commissioned and released today by the Strategies ...
... National Foundation for Cancer Research announced today that renowned ... of Molecular and Experimental Medicine at The Scripps Research ... 5th Annual Szent-Gyrgyi Prize for Progress in Cancer Research. ... humble chicken virus in the early 1960s, has profoundly ...
Cached Biology News:Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 2STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 35th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 25th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded 3
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: